How intelligent technologies are transforming the biopharma industry’Life-changing interventions that have previously been ...

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

William Blair analysts have lowered their FY2027 earnings per share estimate for Bristol-Myers Squibb from $7.70 to $6.50.

Introduction Antitumor antibiotics are a class of chemotherapy drugs derived from natural sources, primarily Streptomyces bacteria, and are wid ...

Shares of Bristol Myers Squibb Co. BMY rose 3.67% to $57.88 Monday, on what proved to be an all-around mixed trading session ...

Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host ...

The application was based on results from the three-arm Phase 3 CheckMate -8HW study.